1
|
Sørensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, Lacoin L, Daumont MJ, Penrod JR, O'Donnell JC, Brustugun OT, Ekman S. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future Oncol 2021; 18:205-214. [PMID: 34784783 DOI: 10.2217/fon-2021-0746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.
Collapse
Affiliation(s)
| | - Pia Horvat
- Real-World Evidence Solutions, IQVIA, London, N1 9JY, UK
| | - Mats Rosenlund
- Real-World & Analytics Solutions, IQVIA, 169 56 Solna, Sweden.,Department of Learning, Informatics, Management & Ethics (LIME), Karolinska Institutet, Stockholm, 171 65, Sweden
| | - Anne Mette Kejs
- Real-World & Analytics Solutions, IQVIA, Copenhagen, 2100, Denmark
| | - Dony Patel
- Real-World Evidence Solutions, IQVIA, London, N1 9JY, UK
| | - Ariadna Juarez-Garcia
- Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Uxbridge, UB8 1DH, UK
| | - Laure Lacoin
- Epi-Fit, Bordeaux, Nouvelle-Aquitaine 33000, France
| | - Melinda J Daumont
- Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, 1420 Braine-L'Alleud, Belgium
| | - John R Penrod
- Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08540, USA
| | - John C O'Donnell
- Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08540, USA
| | - Odd Terje Brustugun
- Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, 3019, Norway
| | - Simon Ekman
- Thoracic Oncology Center, Karolinska University Hospital/Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 171 64, Sweden
| |
Collapse
|